OTC Brands In Hand, Perrigo Prepares To Pump More Revenue From Private Label Portfolio
Executive Summary
“I think that is a value creating opportunity for us as well. We have incredible consumer reach in the US,” says CEO Patrick Lockwood-Taylor. Few companies can say, in “certain categories 80% of the units sold come from us.”
You may also be interested in...
In Consumer Health Serve And Volley, Brands Holding Market Share Against Private Label
Beauty and consumer health care weren’t among the the consumer packaged goods categories showing private label market-share growth during April-June period. Consumer health industry executives see more spending on private label in some categories but without affecting their results.
Perrigo Prepares To Pioneer US OTC Birth Control Sales As ‘Supply Chain Reinvention’ Continues
Firm reports Q2 net sales up 6.4% to $1.2bn while organic measure was 0.8% growth after a 2.7 percentage point drag from SKU prioritization moves. Investment planned over second half to prepare for launch of Opill sales.
Perrigo’s Pivot To Building Brand Market Share Boosted With Opill OTC Oral Contraceptive Approval
Year after acquiring HRA, Perrigo makes preparations to launch arguably the most anticipated OTC switch in US pharma history, Opill with 0.075-mg norgestel. Analysts estimate $100m annual market for OTC birth control.